These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptors by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries.
    Author: Bourgain RH, Andries R, Decuyper K, De Clerck F.
    Journal: J Lipid Mediat; 1991; 3(1):3-11. PubMed ID: 1837488.
    Abstract:
    In rats treated with acetylsalicylic acid (100 mg/kg i.v., -3 h) to block platelet cyclo-oxygenase, a superfusion with tranylcypromine (TCP, 3 x 10(-3) M) plus arachidonic acid (AA; 1 x 10(-4) M) significantly enhances (+70%) the opto-electronically monitored formation of a thrombus, elicited by a superfusion with ADP (4 x 10(-4) M for 45 s) over a de-endothelialized site of a mesenteric artery (200-300 microns diameter). Treatment with ridogrel at doses blocking either singly thromboxane A2 (TxA2) synthetase (0.63 mg/kg i.v., -15 min, n = 6) or additionally TxA2/prostaglandin endoperoxide receptors (5 mg/kg i.v., -15 min, n = 6) reduces (-74%) or abolishes (-100%) respectively the enhancement by TCP + AA of the ADP-induced thrombus formation. These observations demonstrate (1) a transfer of prostaglandin endoperoxides from the vessel wall to the platelets to reinforce thrombus formation in vivo; (2) the antithrombotic potential of combined TxA2 synthetase inhibition plus TxA2/prostaglandin endoperoxide receptor blockade with ridogrel.
    [Abstract] [Full Text] [Related] [New Search]